Literature DB >> 27399352

Vitamin D-Dependent Rickets Type 1 Caused by Mutations in CYP27B1 Affecting Protein Interactions With Adrenodoxin.

Adam Zalewski1, Nina S Ma1, Balazs Legeza1, Nora Renthal1, Christa E Flück1, Amit V Pandey1.   

Abstract

CONTEXT: CYP27B1 converts 25-hydroxyvitamin D3 to active 1,25-dihydroxyvitamin D3, playing a vital role in calcium homeostasis and bone growth. Vitamin D-dependent rickets type 1 (VDDR-1) is a rare autosomal recessive disorder caused by mutations in CYP27B1.
OBJECTIVE: The objective of the study was an enzymatic and structural analysis of mutations in a patient with calcipenic rickets. Design, Setting, Patient, and Intervention: Two siblings presented with calcipenic rickets and normal 1,25-dihydroxyvitamin D3 levels. CYP27B1 gene analysis showed compound heterozygous mutations confirming VDDR-1. We studied wild-type CYP27B1 and mutations H441Y and R459L by computational homology modeling, molecular dynamics simulations, and functional studies using a luciferase assay. The patients were successfully treated with calcitriol. MAIN OUTCOME: The main outcomes of the study were novel mutations leading to a severe loss of CYP27B1 activities for metabolism of 25-hydroxyvitamin D3.
RESULTS: Mitochondrial cytochrome P450s require adrenodoxin (FDX1) and adrenodoxin reductase. We created models of CYP27B1-FDX1 complex, which revealed negative effects of mutations H441Y and R459L. Upon structural analysis, near-identical folds, protein contact areas, and orientations of heme/iron-sulfur cluster suggested that both mutations may destabilize the CYP27B1-FDX1 complex by negating directional interactions with adrenodoxin. This system is highly sensitive to small local changes modulating the binding/dissociation of adrenodoxin, and electron-transporting efficiency might change with mutations at the surface. Functional assays confirmed this hypothesis and showed severe loss of activity of CYP27B1 by both mutations.
CONCLUSIONS: This is the first report of mutations in CYP27B1 causing VDDR-1 by affecting protein-protein interactions with FDX1 that results in reduced CYP27B1 activities. Detailed characterization of mutations in CYP27B1 is required for understanding the novel molecular mechanisms causing VDDR-1.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27399352     DOI: 10.1210/jc.2016-2124

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Evidence of Allosteric Coupling between Substrate Binding and Adx Recognition in the Vitamin D Carbon-24 Hydroxylase CYP24A1.

Authors:  Amit Kumar; P Ross Wilderman; Chengjian Tu; Shichen Shen; Jun Qu; D Fernando Estrada
Journal:  Biochemistry       Date:  2020-04-13       Impact factor: 3.162

2.  Association Between Vitamin D Metabolism Gene Polymorphisms and Risk of Tunisian Adults' Asthma.

Authors:  Oussama Lahmar; Mariem Salhi; Wajih Kaabachi; Anissa Berraies; Jamel Ammar; Munawar Hussain Soomro; Martin Larsen; Isabella Annesi-Maesano; Kamel Hamzaoui; Agnes Hamzaoui
Journal:  Lung       Date:  2018-03-03       Impact factor: 2.584

3.  Characterization of a Cleavable Fusion of Human CYP24A1 with Adrenodoxin Reveals the Variable Role of Hydrophobics in Redox Partner Binding.

Authors:  Natalie Jay; Sean R Duffy; D Fernando Estrada
Journal:  Biochemistry       Date:  2022-01-03       Impact factor: 3.162

4.  Lack of association between CYP27B1 gene polymorphism and type 2 diabetes mellitus in Iranian patients.

Authors:  Saiedeh Erfanian; Abazar Roustazadeh
Journal:  J Diabetes Metab Disord       Date:  2022-03-14

Review 5.  Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein - A position paper from the IFCC Committee on bone metabolism.

Authors:  Konstantinos Makris; Harjit P Bhattoa; Etienne Cavalier; Karen Phinney; Christopher T Sempos; Candice Z Ulmer; Samuel D Vasikaran; Hubert Vesper; Annemieke C Heijboer
Journal:  Clin Chim Acta       Date:  2021-03-10       Impact factor: 6.314

Review 6.  The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine.

Authors:  Niek F Dirks; Mariëtte T Ackermans; Paul Lips; Renate T de Jongh; Marc G Vervloet; Robert de Jonge; Annemieke C Heijboer
Journal:  Nutrients       Date:  2018-04-13       Impact factor: 5.717

7.  Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.

Authors:  Mónica Fernández-Cancio; Núria Camats; Christa E Flück; Adam Zalewski; Bernhard Dick; Brigitte M Frey; Raquel Monné; Núria Torán; Laura Audí; Amit V Pandey
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-29

8.  Variability in Loss of Multiple Enzyme Activities Due to the Human Genetic Variation P284T Located in the Flexible Hinge Region of NADPH Cytochrome P450 Oxidoreductase.

Authors:  Shaheena Parween; Maria Natalia Rojas Velazquez; Sameer S Udhane; Norio Kagawa; Amit V Pandey
Journal:  Front Pharmacol       Date:  2019-10-15       Impact factor: 5.810

9.  Identification of kinase inhibitors that rule out the CYP27B1-mediated activation of vitamin D: an integrated machine learning and structure-based drug designing approach.

Authors:  Kanupriya Mahajan; Himanshu Verma; Shalki Choudhary; Baddipadige Raju; Om Silakari
Journal:  Mol Divers       Date:  2021-07-16       Impact factor: 2.943

10.  Altered CYP19A1 and CYP3A4 Activities Due to Mutations A115V, T142A, Q153R and P284L in the Human P450 Oxidoreductase.

Authors:  Sameer S Udhane; Shaheena Parween; Norio Kagawa; Amit V Pandey
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.